CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges by Matthew J Frigault, Peter A Riedell, Leyla Shune

Get full text

Establishing meaningful change thresholds for European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire CLL‐specific module domain scores: An analysi... by Laurie Eliason, Fatoumata Fofana, Lin Wang, Peter A. Riedell, Shien Guo

Get full text

Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma by Guoshuai Cao, Yifei Hu, Tony Pan, Erting Tang, Nicholas Asby, Thomas Althaus, Jun Wan, Peter A. Riedell, Michael R. Bishop, Justin P. Kline, Jun Huang

Get full text

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

Get full text

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study by Alison Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard C. Hildebrandt, John E. Godwin, Patrick M. Reagan, Nina D. Wagner-Johnston, James Essell, Rajneesh Nath, Scott R. Solomon, Rebecca Champion, Edward Licitra, Suzanne Fanning, Neel K. Gupta, Victor A. Chow, Brenda Yuan, Zhi Yang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon

Get full text